Accessibility Menu
ProQR Therapeutics logo

ProQR Therapeutics(NASDAQ) PRQR

Market Cap$265.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-87%
5 Year-69%
1 Year-5%
1 Month+8%
$1.92
-0.26%
-0.00Today
After hours$1.92+$0.00 (+0.26%)
ProQR Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.922026-08-14
ProQR Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.4%USD 1.882026-08-07
1 month+8.47%USD 1.772026-07-15
3 month+20.75%USD 1.592026-05-15
Year to date-4.95%USD 2.022025-12-31
1 year-4.95%USD 2.022025-08-14
3 year+24.68%USD 1.542023-08-15
5 year-69.48%USD 6.292021-08-13
Since inception-86.97%USD 14.732014-09-18

ProQR Therapeutics Financials at a Glance

Market Cap

$265.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€18.57M

Net Income (TTM)

-€42.40M

EPS (TTM)

-$0.46

P/E Ratio

-4.14

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$1.92

Volume

622,643

Open

$1.91

Previous Close

$1.93

Daily Range

$1.90 - $2.00

52-Week Range

$1.33 - $3.10

Estimated Earnings Date

Nov 5, 2026

PRQR News

optometrist covering her patient’s eyes with an occluder during an eye exam

Why Shares of ProQR Therapeutics Dropped on Wednesday

James HalleyMar 29, 2023
100 bill being cut by a pair of scissors

Why ProQR Therapeutics Stock Got Slammed Again Monday

Eric VolkmanFeb 14, 2022
individual-investor-researching-biotech-stocks

Why ProQR Therapeutics Is Crashing Today

Cory RenauerFeb 11, 2022
excited-invetor-trading-stocks

Here's Why ProQR Stock Surged on Thursday

Cory RenauerSep 9, 2021
gettty-close-up-woman-eyes

An End to This Rare Syndrome Could Be an Opportunity for Investors

Jia Jie ChenApr 7, 2021
GettyImages-680412896

Why ProQR Therapeutics Stock Is Popping Today

Prosper Junior BakinyMar 24, 2021
RNA

Why ProQR Therapeutics N.V. Is Soaring Again Today

Keith SpeightsSep 10, 2018
Chart going up with man holding calculator

3 Biotech Stocks That Soared This Week: Are They Buys?

Keith SpeightsSep 8, 2018
Page 1

PRQR: Motley Fool Moneyball Superscore

47

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-based therapies for genetic disorders. The company is advancing two primary drug candidates in clinical trials, targeting significant genetic conditions affecting vision.

Products and Services
  • Sepofarsen: In Phase II/III trials for Leber Congenital Amaurosis 10
  • Ultevursen: Undergoing Phase II/III evaluation for USH2A-mediated retinitis pigmentosa
  • Axiomer RNA base-editing platform: Proprietary technology for developing novel therapies
Growth Outlook
  • Strong pipeline with two candidates in advanced clinical stages
  • Strategic partnerships with leading institutions enhance research capabilities
  • Focus on genetic disorders presents significant market opportunities
Financial Highlights
  • Recent quarterly revenue of 2.07 million EUR, showing growth potential
  • Cash and cash equivalents of 81.17 million EUR as of March 2026
  • Current ratio of 2.48 indicates strong liquidity position
ProQR Therapeutics N.V. operates in a promising sector with a focus on innovative RNA-based therapies. The company's commitment to addressing genetic disorders through advanced clinical trials positions it well for future growth. With a robust pipeline and strategic collaborations, ProQR is poised to make significant contributions to the biotechnology industry. Recent financial data reflects a solid liquidity position, which may support ongoing research and development efforts. The focus on genetic conditions not only addresses unmet medical needs but also opens avenues for substantial market potential.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

186.6

CEO

Daniel Anton de Boer

Website

www.proqr-tx.com

Headquarters

Leiden, ZH 2333 Ck, NL

PRQR Financials

Key Financial Metrics (TTM)

Gross Margin

92.33%

Operating Margin

-232.71%

Net Income Margin

-228.29%

Return on Equity

-68.44%

Return on Capital

-56.65%

Return on Assets

-31.76%

Earnings Yield

-24.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$265.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

138.09M

Volume

622.64K

Avg. Volume

998.77K

Financials (TTM)

Gross Profit

€17.15M

Operating Income

-€43.22M

EBITDA

-€37.69M

Operating Cash Flow

-€49.14M

Capital Expenditure

-€1.15M

Free Cash Flow

-€50.29M

Cash & ST Invst.

€117.08M

Total Debt

€13.19M

ProQR Therapeutics Performance Analysis

ProQR Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,777,202136.0%
20232023-12-31EUR 7,042,38786.4%
20242024-12-31EUR 20,449,364190.4%
20252025-12-31EUR 17,951,161-12.2%
ProQR Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-23.6%
Q42025-12-3160.8%
Q12026-03-31-55.9%
Q22026-06-30330.9%
ProQR Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.95-16.7%
20232023-12-31EUR -0.38-60.3%
20242024-12-31EUR -0.35-7.1%
20252025-12-31EUR -0.4529.6%
ProQR Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.7%
Q42025-12-3114.9%
Q12026-03-31-52.8%
Q22026-06-3037.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€8.90M

+133.3%

Gross Profit

€8.19M

+114.4%

Gross Margin

91.93%

N/A

Market Cap

$265.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.60M

N/A

Employees

166

N/A

Net Income

-€8.87M

+27.1%

EBITDA

-€8.25M

+28.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€117.08M

-16.7%

Total Debt

€13.19M

-25.3%

Accounts Receivable

€1.86M

-34.7%

Inventory

€0.00

N/A

Long Term Debt

€8.69M

-29.4%

Short Term Debt

€4.50M

-15.8%

Return on Assets

-31.76%

N/A

Return on Invested Capital

-43.82%

N/A

Free Cash Flow

-€12.70M

-10.4%

Operating Cash Flow

-€12.40M

-8.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRDAEntrada Therapeutics, Inc.
$7.32-1.88%
ARCTArcturus Therapeutics Holdings Inc.
$8.14-1.09%
VNDAVanda Pharmaceuticals Inc.
$5.26+0.77%
CAPRCapricor Therapeutics, Inc.
$7.45+12.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About PRQR

What is the current price of ProQR Therapeutics?

ProQR Therapeutics is trading at $1.93 per share.

What is the 52-week range for ProQR Therapeutics?

Over the past 52 weeks, ProQR Therapeutics has traded between $1.33 and $3.10.

How much debt does ProQR Therapeutics have?

As of the most recent reporting period, ProQR Therapeutics reported total debt of €15.08M.

How much cash does ProQR Therapeutics have on hand?

ProQR Therapeutics reported €133.91M in cash and cash equivalents in its most recent financial results.

What is ProQR Therapeutics’s dividend yield?

ProQR Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services